Early Introduction of Tirzepatide Yields T2D Benefits

by | Mar 12, 2026 | Health

Spread the love
Two-year data from Eli Lilly’s SURPASS-EARLY trial show reduced A1c, body weight, and cardiovascular risk factors.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments